450 related articles for article (PubMed ID: 18561878)
1. Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study.
de Bie MK; Lekkerkerker JC; van Dam B; Gaasbeek A; van Buren M; Putter H; van Erven L; Bax JJ; Schalij MJ; Rabelink TJ; Jukema JW
Curr Med Res Opin; 2008 Aug; 24(8):2151-7. PubMed ID: 18561878
[TBL] [Abstract][Full Text] [Related]
2. Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial.
Ottervanger JP; Ramdat Misier AR; Zijlstra F; Schalij MJ; Wever E; Jordaens LJ; Henriques JP; de Boer MJ; Robbe HW; Wellens HJ;
Am Heart J; 2006 Oct; 152(4):636-40. PubMed ID: 16996827
[TBL] [Abstract][Full Text] [Related]
3. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
[TBL] [Abstract][Full Text] [Related]
4. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
8. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
9. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
10. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
Goldenberg I; Moss AJ; McNitt S; Zareba W; Andrews ML; Hall WJ; Greenberg H; Case RB;
Am J Cardiol; 2006 Aug; 98(4):485-90. PubMed ID: 16893702
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of uncertainty, optimism and anxiety in patients receiving their first implantable defibrillator for primary or secondary prevention of sudden cardiac death.
Carroll SL; Arthur HM
Int J Nurs Stud; 2010 Jul; 47(7):836-45. PubMed ID: 20064639
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
Ding L; Hua W; Niu H; Chen K; Zhang S
Europace; 2008 Sep; 10(9):1034-41. PubMed ID: 18559335
[TBL] [Abstract][Full Text] [Related]
13. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
Das M
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
[TBL] [Abstract][Full Text] [Related]
14. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
[TBL] [Abstract][Full Text] [Related]
15. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
[TBL] [Abstract][Full Text] [Related]
16. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
[TBL] [Abstract][Full Text] [Related]
17. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
Prystowsky EN
Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
[TBL] [Abstract][Full Text] [Related]
18. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
[TBL] [Abstract][Full Text] [Related]
19. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
20. Prevention of sudden cardiac death: the role of the implantable cardioverter-defibrillator.
Sinha SK; Mehta D; Gomes JA
Mt Sinai J Med; 2005 Jan; 72(1):1-9. PubMed ID: 15682255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
